Sentences with phrase «for diseases of»

SENS Research Foundation is a 501 (c)(3) nonprofit that works to research, develop, and promote comprehensive regenerative medicine solutions for the diseases of aging.

Development of treatments for diseases of the central nervous system, Feng says, «has essentially stalled.»

WRAIR develops vaccines, drugs and diagnostics for these diseases of importance to military and public health.

EVI's main focus remains on the discovery of antigens for diseases of poverty and their introduction into early stages of clinical development.

BioBright, a firm dedicated to creating the smart laboratory of the future, has announced a collaboration with the Wellcome Sanger Institute that could lead to the faster development of drugs for diseases of the immune system like rheumatoid arthritis.

The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient's own skin cells for diseases of the central nervous system (CNS).

The thoracic surgeons at the University of Chicago Medicine offer patients the latest treatment options — including video - assisted and robotic procedures — for diseases of the lungs, esophagus and mediastinum.

EVI is a non-profit Product Development Partnership supporting the development of vaccines for diseases of poverty by bridging conceptual and operational gaps in translational research.

Seeking to align all major stakeholders and acting as a focal point to ensure the successful development of vaccines for diseases of poverty for low income populations.

«If we can expand the role of RNAi to other organ systems beyond the liver, the likelihood that RNAi could overtake antibodies in terms of importance for diseases of man, animals, and even plants, is certainly there,» said Dr. Geert Cauwenbergh, president and CEO of RXi Pharmaceuticals.

This has been recognized for years but not particularly acted upon until the Gates Foundation came along and restarted or energized a lot of research for diseases of the poor.

Stem cell treatments are already a reality for diseases of the blood, such as leukemia and sickle - cell anemia (like Paizley's), and for tissue repair of the skin and the cornea.

Pleasure, who is research director at Shriner's Hospital for Children Northern California and also directs the Institute for Pediatric Regenerative Medicine, noted that considerable research interest has arisen about the use of minocycline for diseases of the central nervous system because of the increasing evidence about its neuroprotective effects.

The doctors and nurses of Pediatric Neurosurgery provide surgical care for all diseases of the brain and spine, including:

The Neurology Division at the Floating Hospital for Children in Boston offers comprehensive evaluation, consultation and management for diseases of the central, peripheral and autonomic nervous systems and the musculoskeletal system.

Find the expertise your child needs from top pediatric neurologists at Floating Hospital in Boston, offering quality care for diseases of the nervous system.

He has in himself a susceptibility for the disease of double - mindedness.

Not exact matches

Meanwhile, about half of all Americans have at least one chronic disease, which is accounting for 80 % of the healthcare costs.

About 69 million employees in the U.S. say they miss work because of health problems every year, which reduces economic output by $ 260 billion per year, according to the Centers for Disease Control and Prevention.

Heart disease is the leading cause of death for men and women in the U.S. Every year over 700,000 Americans have a heart attack and half of those are fatal.

«We're in a serious jam,» says Gerry Wright, director of the Michael DeGroote Institute for Infectious Disease Research at McMaster University.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The PGS platform promised genetic risk reports for more than 250 disease at the time — but, after the FDA smackdown, 23andMe was forced to stop marketing the service and pursue a piecemeal strategy of winning regulatory approval of individual tests.

That means that, for the first time ever, Americans won't have to get a prescription to receive plain - English medical reports about their chances of developing diseases like Alzheimer's, Parkinson's disease, celiac disease, and other disorders based on analyses of their genetic makeup.

The Bahamian - American physician and special adviser to the Carter Center is one of the key individuals responsible for the eradication of smallpox — a truly terrifying disease that in the 20th century alone killed as many as 300 million people.

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

The project's launch featured a prominent ALS patient and research advocate: Pat Quinn, co-founder of the ALS Ice Bucket Challenge, an initially - derided social media stunt that went on to raise hundreds of millions of dollars for ALS research and may have spurred important new discoveries about the disease's genetic roots.

One research project, for example, focuses on using robots to recognize the facial reactions of Parkinson's Disease patients who have lost the ability to convey emotion to others because of reduced muscle activity.

Sitting for long periods of time puts you at risk of cardiovascular or metabolic diseases.

«If we determine that our [treatment] can prevent or delay the onset of symptoms in healthy yet high - risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.»

A study of increases or decreases in rates of a disease across years, calculated for groups of people, is called an ecologic study.

Founded in 2011, Innovent has built a portfolio of 16 potential products for treating cancer, autoimmune disorders and other diseases, and seven of those are in clinical development.

The acquisition is meant to build on Takeda's forays into drugs for gastrointestinal disorders; TiGenix is on the cusp of securing a European regulatory approval for a treatment for Crohn's disease.

Xenex goes after some of the hardest - to - kill pathogens, including C. difficile, which is linked to 14,000 American deaths each year, according to the Centers for Disease Control and Prevention.

When considering the fact that in the US, 2,684,803 mothers had a vaginal birth and 1,258,581 mothers had a c - section in 2016, according to the Centers for Disease Control and Prevention, that's a lot of money going into the healthcare system just from maternity costs.

In a year that saw a terrible Ebola pandemic in Africa and the resurgence of Legionnaire's disease in New York, it's small wonder that life sciences and health - care companies are also leading the way for initial public offerings.

Danish pharma company Novo Nordisk (nvo), best known for its insulin - based treatments for diabetes, said Tuesday it's going to shift its focus slightly to fighting obesity, one of the primary causes of that disease.

Following the death of a man in Texas who was infected with Ebola, hospitals across the country are bracing themselves for the possibility of having to manage the deadly disease.

Scanadu will also have anonymized access to all of its users» health data, which can be used for epidemiology — the study of the patterns of health and disease in defined geographic areas.

He spoke 10 languages and objected to many ancient medical treatments, including the practice of bloodletting, but he also suggested that coffee was responsible for many diseases.

«For the first time, scientists have attempted to account for numbers of people with biomarkers or other evidence of possible preclinical Alzheimer's disease, but who do not have impairment or Alzheimer's dementFor the first time, scientists have attempted to account for numbers of people with biomarkers or other evidence of possible preclinical Alzheimer's disease, but who do not have impairment or Alzheimer's dementfor numbers of people with biomarkers or other evidence of possible preclinical Alzheimer's disease, but who do not have impairment or Alzheimer's dementia.

According to data from the National Center for Health Statistics (NCHS), a branch of the Centers for Disease Control and Prevention, the life expectancy for a baby born in 2016 fell to 78.6 years, which is a small but statistically significant decline of 0.1 percent.

For one thing, «There are a lot of good drugs on the market for heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with FortuFor one thing, «There are a lot of good drugs on the market for heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with Fortufor heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with Fortune.

So how does biopharma reverse its R&D ROI rut while also innovating newer, better treatments for the diseases afflicting millions of people?

or, more radically, for posting their genetic data to an anonymized, shared research database that might be used to identify those at risk for certain diseases or to identify those who respond better to specific classes of drugs, from beta blockers to cancer medicines.

• Rani Therapeutics, a San Jose, Calif. - based developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, raised $ 53 million in funding.

For a century and a half, epidemiology has been an effective strategy for tracing the root causes of infectious disease outbreaks — as John Snow demonstrated in 1854, when he painstakingly mapped cases of cholera in London and eventually traced them to a single contaminated well and water pump in the Soho district of the ciFor a century and a half, epidemiology has been an effective strategy for tracing the root causes of infectious disease outbreaks — as John Snow demonstrated in 1854, when he painstakingly mapped cases of cholera in London and eventually traced them to a single contaminated well and water pump in the Soho district of the cifor tracing the root causes of infectious disease outbreaks — as John Snow demonstrated in 1854, when he painstakingly mapped cases of cholera in London and eventually traced them to a single contaminated well and water pump in the Soho district of the city.

In addition to writing several best - selling books like The Road Ahead, The Bill and Melinda Gates Foundation has raised billions of dollars to combat infectious diseases and elevate the quality of life for impoverished nations around the globe.

Cases of tick - and mosquito - borne diseases more than triple since 2004, according to a new study by the Centers for Disease Control and Prevention.

Luckily, the US Centers for Disease Control and Prevention has some specific steps you can take to kill as many of the infuriating creatures as possible.